“…2A–C), consistent with a defect in diastolic function. The mitral deceleration time did not change (Table 3), and the mRNA expression of SERCA (sarco/endoplasmic reticulum calcium ATPase) and its phospholambin regulator (PLN), which are frequently, but not invariably [28, 29], diminished with diastolic dysfunction, were not altered in Acsl1 H−/− mice before or after rapamycin treatment (SERCA1/2: vehicle control, 1.11±0.24; rapamycin control, 1.41±0.35; vehicle Acsl1 H−/− , 0.83±0.09; rapamycin Acsl1 H−/− , 1.16±0.15; PLN: vehicle control, 1.11±0.0.21; rapamycin control, 1.33±0.25; vehicle Acsl1 H−/− , 0.85±0.09; rapamycin Acsl1 H−/− , 1.23±0.14; n=5–6). Because the 10 week rapamycin treatment itself induced diastolic dysfunction in both control and Acsl1 deficient mice, as previously described [30–32], it was not possible to interpret the effects of Acsl1-related mTOR activity on diastolic function.…”